---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-068597"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:22:56.545318+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Unicycive Q2 net income $3.0M; OLC NDA on track for August 2024

## Summary
- OLC pivotal trial: 1.4% discontinuation rate (evaluable) for treatment-related AEs; no SAEs.
- Patient survey: 79% preferred OLC, 98% found it easy to take, 89% satisfied.
- UNI-494 Phase 1 enrollment completed; data expected Q3 2024; new patent granted until 2040.
- R&D expenses $4.9M (up $2.6M YoY); cash $41.8M, sufficient into 2026.
- Diluted EPS loss $0.15; basic EPS $0.08 due to warrant liability fair value change.

## SEC filing metadata
- accession: 0001213900-24-068597
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390024068597/0001213900-24-068597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390024068597/ea0211321-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-068597
- JSON: https://secwatch.observer/filing/0001213900-24-068597.json
- Plain text: https://secwatch.observer/filing/0001213900-24-068597.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.